Date:	May 6 th 2021	
Your Nam	e: Ning Su	
Manuscri	pt Title: Efficacy	and safety of anlotinib in metastatic adenoid cystic carcinoma: a retrospective study
Manuscrii	nt number (if kn	own): TCR-21-2433

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	X _None	pranning of the work
3	Grants or contracts from any entity (if not indicated in item #1 above). Royalties or licenses	Time frame: past X _None X _None	36 months
4	Consulting fees	_ X _None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X_None	
6	Payment for expert testimony	X_None	
7	Support for attending meetings and/or travel	_ X _None	
8	Patents planned, issued or pending	_ X _None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	_ X _None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_ X _None	
11	Stock or stock options	_ X _None	
12	Receipt of equipment, materials, drugs, medical	X_None	
	writing, gifts or other services		
13	Other financial or non-	_ X _None	
	financial interests		

None.			

Please place an "X" next to the following statement to indicate your agreement:

Date:	Mar 6 th 2022	
Your Na	me: Yu Fang	
Manusc	ript Title: Efficacy	and safety of anlotinib in metastatic adenoid cystic carcinoma: a retrospective study
Manusc	rint number (if kn	own): TCP-21-2/33

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_ X _None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None	
3	Royalties or licenses	X_None	
4	Consulting fees	X_None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X_None	
6	Payment for expert testimony	X_None	
7	Support for attending meetings and/or travel	_ X _None	
8	Patents planned, issued or pending	_ X _None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	_ X _None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_ X _None	
11	Stock or stock options	_ X _None	
12	Receipt of equipment, materials, drugs, medical	X_None	
	writing, gifts or other services		
13	Other financial or non-	_ X _None	
	financial interests		

None.			

Please place an "X" next to the following statement to indicate your agreement:

Date:	May 6 th	2021							
Your I	Name: <u>Jinni</u>	Wang							_
Manu	script Title:_ <u>E</u>	fficacy ar	nd safety of anlotin	ib in metastatio	adenoid	cystic carci	noma: a ret	rospective s	tudy
Manu	script numbe	r (if know	/n): TCR-21-2433-	•					•

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	X _None	pranning of the work
3	Grants or contracts from any entity (if not indicated in item #1 above). Royalties or licenses	Time frame: past X _None X _None	36 months
4	Consulting fees	_ X _None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X_None	
6	Payment for expert testimony	X_None	
7	Support for attending meetings and/or travel	_ X _None	
8	Patents planned, issued or pending	_ X _None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	_ X _None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_ X _None	
11	Stock or stock options	_ X _None	
12	Receipt of equipment, materials, drugs, medical	X_None	
	writing, gifts or other services		
13	Other financial or non-	_ X _None	
	financial interests		

None.			

Please place an "X" next to the following statement to indicate your agreement:

Date:	May 6 th 2021
Your Name	e: Xiaopeng Tian
Manuscrip	t Title: Efficacy and safety of anlotinib in metastatic adenoid cystic carcinoma: a retrospective study
Manuscrip	t number (if known): TCR-21-2433

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	National Natural Science Foundation of China (No. 81973384) Time frame: past	
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None	
3	Royalties or licenses	_ X _None	
4	Consulting fees	_ X _None	

_			
5	Payment or honoraria for lectures, presentations,	_ X _None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_ X _None	
	testimony		
7	Support for attending	_ X _None	
	meetings and/or travel		
0	Determination and increase an	V. None	
8	Patents planned, issued or	_ X _None	
	pending		
_			
9	Participation on a Data	_ X _None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_ X _None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_ X _None	
12	Receipt of equipment,	_ X _None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	_ X _None	
	financial interests		

The author reports grants from National Natural Science Foundation of China (No. 81973384).

Please place an "X" next to the following statement to indicate your agreement:

Date:	May 6 th 2021	
Your Na	me: Shuyun Ma	
Manuso	ript Title:_Efficacy	and safety of anlotinib in metastatic adenoid cystic carcinoma: a retrospective study
Manuso	ript number (if kno	own): TCR-21-2433

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_ X _None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X _None	
3	Royalties or licenses	_ X _None	
4	Consulting fees	X_None	
5		_ X _None	

	Payment or honoraria for lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_ X _None	
	testimony		
7	Support for attending meetings and/or travel	_ X _None	
	-		
8	Patents planned, issued or	_ X _None	
	pending		
9	Participation on a Data	_ X _None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_ X _None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	X None	
	·		
12	Receipt of equipment,	_ X _None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	_ X _None	
	financial interests		

None.			

Please place an "X" next to the following statement to indicate your agreement:

Date:_	May 6 th 2022	
Your N	lame: <u>Jun Cai</u>	
Manus	script Title: Efficacy and s	safety of anlotinib in metastatic adenoid cystic carcinoma: a retrospective stud
Manus	scrint number (if known):	TCR-21-2433

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	X _None	
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_ X _None	
	any entity (if not indicated in item #1 above).		
3	Royalties or licenses	X None	
	,		
4	Consulting fees	_ X _None	
5		X None	

	Payment or honoraria for lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_ X _None	
	testimony		
7	Support for attending meetings and/or travel	_ X _None	
	-		
8	Patents planned, issued or	_ X _None	
	pending		
9	Participation on a Data	_ X _None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_ X _None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	X None	
	·		
12	Receipt of equipment,	_ X _None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	_ X _None	
	financial interests		

None.			

Please place an "X" next to the following statement to indicate your agreement:

Date:	May 6 th 2021	
Your Nam	e:Yuchen Zhang	
Manuscrij	ot Title: Efficacy an	d safety of anlotinib in metastatic adenoid cystic carcinoma: a retrospective study
Manuscrii	nt number (if know	n)· TCR-21-2433

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initialX _None	pranning of the work
3	Grants or contracts from any entity (if not indicated in item #1 above). Royalties or licenses	Time frame: past X _None X _None	36 months
4	Consulting fees	_ X _None	

6	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	X_None	
7	Support for attending meetings and/or travel	_ X _None	
8	Patents planned, issued or pending	X_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X_None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X _None	
11	Stock or stock options	_ X _None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_ X _None	
13	Other financial or non- financial interests	_ X _None	

None.			

Please place an "X" next to the following statement to indicate your agreement:

Date:	May 6 th 20	21
Your Na	ame: <u>Yi Xia</u>	
Manus	cript Title: Effic	acy and safety of anlotinib in metastatic adenoid cystic carcinoma: a retrospective study
Manus	cript number (if	known): TCR-21-2433

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_ X _None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X _None	
3	Royalties or licenses	_ X _None	
4	Consulting fees	X_None	
5		_ X _None	

6	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	_ X _None	
7	Support for attending meetings and/or travel	_ X _None	
8	Patents planned, issued or pending	X_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	_ X _None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X_None	
11	Stock or stock options	_ X _None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_ X _None	
13	Other financial or non- financial interests	_ X _None	

None.		

Please place an "X" next to the following statement to indicate your agreement:

Date:_	May 25th 2021	
Your N	lame: <u>Panpan Liu</u>	
Manus	script Title: Efficacy	and safety of anlotinib in metastatic adenoid cystic carcinoma: a retrospective study
Manus	script number (if kno	wn): TCR-21-2433

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial _X_None	pranning of the work
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past _ X _None	36 months
3	Royalties or licenses	_ X _None	
4	Consulting fees	_ X _None	

6	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	X_None	
7	Support for attending meetings and/or travel	_ X _None	
8	Patents planned, issued or pending	X_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X_None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X _None	
11	Stock or stock options	_ X _None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_ X _None	
13	Other financial or non- financial interests	_ X _None	

None.			

Please place an "X" next to the following statement to indicate your agreement:

Date:	May 6 th 2022	
Your Nam	e: Qingqing Cai	
Manuscri	pt Title: Efficacy and sa	fety of anlotinib in metastatic adenoid cystic carcinoma: a retrospective study
Manuscrii	nt number (if known):	TCR-21-2433

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Special Support Program of Sun Yat-sen University Cancer Center (No. PT19020401) Science and Technology Planning Project of Guangzhou, China (No. 202002030205) Clinical Oncology Foundation of Chinese Society of Clinical Oncology (No. Y-XD2019-124)			Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: past 36 months	1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Special Support Program of Sun Yat-sen University Cancer Center (No. PT19020401) Science and Technology Planning Project of Guangzhou, China (No. 202002030205) Clinical Oncology Foundation of Chinese Society of Clinical Oncology (No. Y-XD2019- 124)	

2	Grants or contracts from any entity (if not indicated in item #1 above).	X _None
3	Royalties or licenses	X_None
4	Consulting fees	X _None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X_None
6	Payment for expert testimony	X _None
7	Support for attending meetings and/or travel	_ X _None
8	Patents planned, issued or pending	X_None
9	Participation on a Data Safety Monitoring Board or Advisory Board	_ X _None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X _None
11	Stock or stock options	X_None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X _None
13	Other financial or non- financial interests	X_None

The author reports grants from the Special Support Program of Sun Yat-sen University Cancer Center (No. PT19020401), the Science and Technology Planning Project of Guangzhou, China (No. 202002030205), and the Clinical Oncology Foundation of Chinese Society of Clinical Oncology (No. Y-XD2019-124).

Please place an "X" next to the following statement to indicate your agreement:				
_ X _ I certify that I have answered every question and have not altered the wording of any of the questions on this form.				